Business
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
NEW YORK, February 03, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF’3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The study had two objectives:
About this update from Pfizer, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/a654442abb5efb738aaf782af8d9564e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9.3ziqX.5PtW1jFlHk6ZoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a654442abb5efb738aaf782af8d9564e","width":480,"height":212}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher dosing regimens in Phase 3","length":137,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Study met primary endpoint of statistically significant weight reduction at 28 weeks with a competitive tolerability profile","length":124,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Weight loss continued after pre-planned switch from weekly to monthly dosing, with no plateau observed at 28 weeks","length":114,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"10 Phase 3 trials with PF’3944 expected to advance in 2026; expansive clinical development program underway with 20+ planned and ongoing studies across diverse obesity pipeline","length":176,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":551,"olType":false},{"type":"text","content":"NEW YORK, February 03, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF’3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The study had two objectives:","length":374,"tagName":"p"},{"type":"text","content":"(1) to demonstrate PF’3944 could achieve continued weight loss when switching from weekly to monthly subcutaneous injections and maintain its efficacy while reducing the dosing frequency four-fold; and(2) to demonstrate PF’3944 could switch to a four-fold equivalent monthly dose while maintaining a well-tolerated and favorable safety profile.","length":345,"tagName":"p","attribs":{}},{"type":"text","content":"The study demonstrated statistically significant weight reduction...